To study the efficacy of probiotic Lactobacillus rhamnosus GG in reducing gut derived Uremic toxin in chronic kidney disease patients before receiving renal replacement therapy. To study the efficacy of probiotic Lactobacillus rhamnosus GG in reducing gut derived Uremic toxin in chronic kidney disease patients before receiving renal replacement therapy.
Conditions
Interventions
probiotic from heathy people,starch placebo
Experimental Drug,Placebo Comparator Drug
Probiotic, Lactobacillus rhamnosus GG,placebo
Sponsors
Ratchadapiseksompotch Research Fund
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age > 18 years old Diagnosed CKD stage 3-5 or estimated glomerular filtration rate (eGFR) between 10-60 ml/min/mm2 who did not undergo renal replacement therapy
Exclusion criteria
Exclusion criteria: Estimated glomerular filtration rate (eGFR ) less than 10 ml/min/mm2 History of kidney transplant On immunosuppressive therapy History of Renal replace therapy except RRT from acute kidney failure Pregnancy at date of participation Diagnosed Inflammatory bowel disease or infection at bowel Diagnosed Cancer who has to ongoing Chemotherapy or in stage 4 End-stage diseases : Congestive heart failure NYHA 4, End-stage lung diseases, Cirrhosis Child-Pugh B,C, or patient who has Karnofsky performance score less than 40
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum IS, PCS 8 weeks Immunoassay | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR (CKD-EPI) 8 wk Blood quantity,IL-6 8 wk Immunoassay,IL-10 8 wk Immunoassay,Endotoxin activity assay 8 wk Endotoxin activity assay,GI symptoms score 8 wk Questionaired | — |
Countries
Thailand
Contacts
Public Contactsedthasith treewatchareekorn
King chulalongkorn memorial hospital
Outcome results
None listed